Table of Contents
International Journal of Peptides
Volume 2012, Article ID 965238, 19 pages
http://dx.doi.org/10.1155/2012/965238
Review Article

Antimicrobial Peptides as Infection Imaging Agents: Better Than Radiolabeled Antibiotics

Nuclear Medicine Division, Punjab Institute of Nuclear Medicine (PINUM), Faisalabad 38000, Pakistan

Received 8 December 2011; Revised 9 February 2012; Accepted 11 March 2012

Academic Editor: Mirian A. F. Hayashi

Copyright © 2012 Muammad Saeed Akhtar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Levy, “Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents,” Blood, vol. 96, no. 8, pp. 2664–2672, 2000. View at Google Scholar · View at Scopus
  2. M. R. Yeaman, A. S. Ibrahim, J. E. J. Edwards, A. S. Bayer, and M. A. Ghannoum, “Thrombin-induced rabbit platelet microcidal protein is fungicidal in vitro,” Antimicrob Agents Chemother, vol. 37, pp. 546–553, 1993. View at Google Scholar
  3. S. S. Das, A. V. Hall, D. W. Wareham, and K. E. Britten, “Infection imaging with radiopharmaceuticals in the 21st century,” Brazilian Archives of Biology and Technology, vol. 45, pp. 25–37, 2002. View at Google Scholar
  4. F. H. M. Corstens and J. W. M. Van Der Meer, “Nuclear medicine's role in infection and inflammation,” Lancet, vol. 354, no. 9180, pp. 765–770, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. Peters, H. J. Danpure, S. Osman et al., “Preliminary clinical experience with 99mTc-hexamethylpropylene-amineoxime for labelling leucocytes and imaging infection,” The Lancet, vol. 2, pp. 945–949, 1986. View at Google Scholar
  6. A. M. Peters, “The utility of [99mTc]HMPAO-leukocytes for imaging infection,” Seminars in Nuclear Medicine, vol. 24, no. 2, pp. 110–127, 1994. View at Google Scholar · View at Scopus
  7. S. Gratz, H. J. J. M. Rennen, O. C. Boerman et al., “99mTc-HMPAO-labeled autologous versus heterologous leukocytes for imaging infection,” Journal of Nuclear Medicine, vol. 43, no. 7, pp. 918–924, 2002. View at Google Scholar · View at Scopus
  8. W. Becker and J. Meller, “The role of nuclear medicine in infection and inflammation,” Lancet Infectious Diseases, vol. 1, no. 5, pp. 326–333, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Love and C. J. Palestro, “Radionuclide imaging of infection,” Journal of Nuclear Medicine Technology, vol. 32, no. 2, pp. 47–57, 2004. View at Google Scholar · View at Scopus
  10. L. Filippi and O. Schillaci, “Usefulness of hybrid SPECT/CT in 99mTC-HMPAO-labeled leukocyte scintigraphy for bone and joint infections,” Journal of Nuclear Medicine, vol. 47, no. 12, pp. 1908–1913, 2006. View at Google Scholar · View at Scopus
  11. R. Bar-Shalom, N. Yefremov, L. Guralnik et al., “SPECT/CT using 67Ga and 111In-labeled leukocyte scintigraphy for diagnosis of infection,” Journal of Nuclear Medicine, vol. 47, no. 4, pp. 587–594, 2006. View at Google Scholar · View at Scopus
  12. N. Dumarey, D. Egrise, D. Blocklet et al., “Imaging infection with 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients,” Journal of Nuclear Medicine, vol. 47, no. 4, pp. 625–632, 2006. View at Google Scholar · View at Scopus
  13. B. Fournier, X. Zhao, T. Lu, K. Drlica, and D. C. Hooper, “Selective targeting of topoisomerase IV and DNA gyrase in Stphylococcus aureus: different patterns of quinolone-induced inhibition of DNA Synthesis,” Antimicrob Agents Chemother, vol. 44, pp. 2160–2165, 2000. View at Google Scholar
  14. Z. Yapar, M. Kibar, A. F. Yapar, E. Toǧrul, U. Kayaselçuk, and Y. Sarpel, “The efficacy of technetium-99m ciprofloxacin (Infecton) imaging in suspected orthopaedic infection: a comparison with sequential bone/gallium imaging,” European Journal of Nuclear Medicine, vol. 28, no. 7, pp. 822–830, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Sonmezoglu, M. Sonmezoglu, M. Halac et al., “Usefulness of 99mTc-ciprofloxacin (infecton) scan in diagnosis of chronic orthopedic infections: comparative study with 99mTc-HMPAO leukocyte scintigraphy,” Journal of Nuclear Medicine, vol. 42, no. 4, pp. 567–574, 2001. View at Google Scholar · View at Scopus
  16. M. J. Larikka, A. K. Ahonen, O. Niemela et al., “99mTc-ciproflaxacin (infection) imaging in the diagnosis of knee prosthesis infections,” Nuclear Medicine Communications, vol. 23, pp. 167–170, 2002. View at Google Scholar
  17. L. Sarda, A. C. Crémieux, Y. Lebellec et al., “Inability of 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases,” Journal of Nuclear Medicine, vol. 44, no. 6, pp. 920–926, 2003. View at Google Scholar · View at Scopus
  18. T. Appelboom, P. Emery, L. Tant, N. Dumarey, and A. Schoutens, “Evaluation of technetium-99m-ciprofloxacin (infection) for detecting sites of inflammation in arthritis,” Rheumatology, vol. 42, no. 10, pp. 1179–1182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. E. Jones, N. M. Boenink, J. Verhoef, K. Kohrer, and F. J. Schmitz, “Multiple mutations conferring ciprofloxacin resistance in staphylococcus aureus demonstrate long-term stability in an antibiotic free environment,” Journal of Antimicrobial Chemotherapy, vol. 45, pp. 353–356, 2000. View at Google Scholar
  20. M. Zasloff, “Antimicrobial peptides of multicellular organisms,” Nature, vol. 415, no. 6870, pp. 389–395, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. M. Welling, P. H. Nibbering, A. Paulusma-Annema, P. S. Hiemstra, E. K. J. Pauwels, and W. Calame, “Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1,” Journal of Nuclear Medicine, vol. 40, no. 12, pp. 2073–2080, 1999. View at Google Scholar · View at Scopus
  22. P. S. Hiemstra, M. T. Van Den Barselaar, M. Roest, P. H. Nibbering, and R. Van Furth, “Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages,” Journal of Leukocyte Biology, vol. 66, no. 3, pp. 423–428, 1999. View at Google Scholar · View at Scopus
  23. M. M. Welling, S. Mongera, A. Lupetti et al., “Radiochemical and biological characteristics of 99mTc-UBI 29-41 for imaging of bacterial infections,” Nuclear Medicine and Biology, vol. 29, no. 4, pp. 413–422, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Welling, A. Lupetti, H. S. Balter et al., “99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections,” Journal of Nuclear Medicine, vol. 42, no. 5, pp. 788–794, 2001. View at Google Scholar · View at Scopus
  25. R. M. Epand and H. J. Vogel, “Diversity of antimicrobial peptides and their mechanisms of action,” Biochimica et Biophysica Acta, vol. 1462, no. 1-2, pp. 11–28, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Edgerton, S. E. Koshlukova, T. E. Lo, B. G. Chrzan, R. M. Straubinger, and P. A. Raj, “Candidacidal activity of salivary histatins: identification of a histatin 5-binding protein on Candida albicans,” Journal of Biological Chemistry, vol. 273, no. 32, pp. 20438–20447, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. M. S. Akhtar, J. Iqbal, M. A. Khan et al., “99mTc-labeled antimicrobial peptide ubiquicidin (29-41) accumulates less in Escherichia coli infection than in Staphlococcus aureus infection,” Journal of Nuclear Medicine, vol. 45, no. 5, pp. 849–856, 2004. View at Google Scholar · View at Scopus
  28. M. S. Akhtar, M. E. Khan, B. Khan et al., “An imaging analysis of 99mTc-UBI (29-41) uptake in S. aureus infected thighs of rabbits on ciprofloxacin treatment,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 6, pp. 1056–1064, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. S. Akhtar, A. Qaisar, J. Irfanullah et al., “Antimicrobial peptide 99mTc-Ubiquicidin 29-41 as human infection-imaging agent: clinical trial,” Journal of Nuclear Medicine, vol. 46, no. 4, pp. 567–573, 2005. View at Google Scholar · View at Scopus
  30. Y. Ito, S. Okuyama, T. Awano, K. Takahashi, and T. Sato, “Diagnostic evaluation of 67 Ga scanning of lung cancer and other diseases.,” Radiology, vol. 101, no. 2, pp. 355–362, 1971. View at Google Scholar · View at Scopus
  31. R. D. Neuman and J. G. McAfee, “Gallium-67 imaging in infection,” in Diagnostic Nuclear Medicine, M. P. Sandler, J. A. Patton, R. E. Coleman, A. Gottschalk, F. J. Wackers, and P. B. Hoffer, Eds., pp. 1493–1507, Williams and Wilkins, Baltimore, Md, USA, 3rd edition, 1996. View at Google Scholar
  32. M. F. Tsan, “Mechanism of gallium-67 accumulation in inflammatory lesions,” Journal of Nuclear Medicine, vol. 26, no. 1, pp. 88–92, 1985. View at Google Scholar · View at Scopus
  33. R. K. Zeman and T. W. Ryerson, “The value of bowel preparation in Ga-67 citrate scanning: concise communication,” Journal of Nuclear Medicine, vol. 18, no. 9, pp. 886–889, 1977. View at Google Scholar · View at Scopus
  34. O. James, E. J. Wood, and S. Sherlock, “67Gallium scanning in the diagnosis of liver disease,” Gut, vol. 15, no. 5, pp. 404–410, 1974. View at Google Scholar · View at Scopus
  35. D. Front, O. Israel, R. Epelbaum et al., “Ga-67 SPECT before and after treatment of lymphoma,” Radiology, vol. 175, no. 2, pp. 515–519, 1990. View at Google Scholar · View at Scopus
  36. C. J. Palestro, “The current role of gallium imaging in infection,” Seminars in Nuclear Medicine, vol. 24, no. 2, pp. 128–141, 1994. View at Google Scholar · View at Scopus
  37. E. V. Staab and W. H. McCartney, “Role of Gallium 67 in inflammatory disease,” Seminars in Nuclear Medicine, vol. 8, no. 3, pp. 219–234, 1978. View at Google Scholar · View at Scopus
  38. M. A. Auler, S. Bagg, and L. Gordon, “The role of nuclear medicine in imaging infection,” Seminars in Roentgenology, vol. 42, no. 2, pp. 117–121, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. A. J. Fischman, R. H. Rubin, J. A. White et al., “Localization of Fc and Fab fragments of nonspecific polyclonal IgG at focal sites of inflammation,” Journal of Nuclear Medicine, vol. 31, no. 7, pp. 1199–1205, 1990. View at Google Scholar · View at Scopus
  40. A. J. Fischman, A. J. Fucello, J. L. Pellegrino-Gensey et al., “Effect of carbohydrate modification on the localization of human polyclonal IgG at focal sites of bacterial infection,” Journal of Nuclear Medicine, vol. 33, no. 7, pp. 1378–1382, 1992. View at Google Scholar · View at Scopus
  41. M. W. Nijhof, W. J. G. Oyen, A. Van Kämpen, R. A. M. J. Ciaessens, J. W. M. Van Der Meer, and F. H. M. Corstens, “Evaluation of infections of the locomotor system with indium-111 -labeled human IgG scintigraphy,” Journal of Nuclear Medicine, vol. 38, no. 8, pp. 1300–1305, 1997. View at Google Scholar · View at Scopus
  42. J. R. Buscombe, W. J. G. Oyen, A. Grant et al., “Indium-111-labeled polyclonal human immunoglobulin: identifying focal infection in patients positive for human immunodeficiency virus,” Journal of Nuclear Medicine, vol. 34, no. 10, pp. 1621–1625, 1993. View at Google Scholar · View at Scopus
  43. L. Mairal, P. A. De Uma, J. Martin-Comin et al., “Simultaneous administration of 111In-human immunoglobulin and 99mTc-HMPAO labelled leucocytes in inflammatory bowel disease,” European Journal of Nuclear Medicine, vol. 22, no. 7, pp. 664–670, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Becker, J. Bair, T. Behr et al., “Detection of soft-tissue infections and osteomyelitis using a technetium- 99m-labeled anti-granulocyte monoclonal antibody fragment,” Journal of Nuclear Medicine, vol. 35, no. 9, pp. 1436–1443, 1994. View at Google Scholar · View at Scopus
  45. O. C. Boerman, G. Storm, W. J. G. Oyen et al., “Sterically stabilized liposomes labeled with Indium-111 to image focal infection,” Journal of Nuclear Medicine, vol. 36, no. 9, pp. 1639–1644, 1995. View at Google Scholar · View at Scopus
  46. P. Laverman, E. T. M. Dams, W. J. G. Oyen et al., “A novel method to label liposomes with 99mTc by the hydrazino nicotinyl derivative,” Journal of Nuclear Medicine, vol. 40, no. 1, pp. 192–197, 1999. View at Google Scholar · View at Scopus
  47. E. T. M. Dams, W. J. G. Oyen, O. C. Boerman et al., “99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation,” Journal of Nuclear Medicine, vol. 41, no. 4, pp. 622–630, 2000. View at Google Scholar · View at Scopus
  48. D. J. Hnatowich, F. Virzi, and M. Rusckowski, “Investigations of avidin and biotin for imaging applications,” Journal of Nuclear Medicine, vol. 28, no. 8, pp. 1294–1302, 1987. View at Google Scholar · View at Scopus
  49. M. Rusckowski, B. Fritz, and D. J. Hnatowich, “Localization of infection using streptavidin and biotin: an alternative to nonspecific polyclonal immunoglobulin,” Journal of Nuclear Medicine, vol. 33, no. 10, pp. 1810–1815, 1992. View at Google Scholar · View at Scopus
  50. A. Samuel, G. Paganelli, R. Chiesa et al., “Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy,” Journal of Nuclear Medicine, vol. 37, no. 1, pp. 55–61, 1996. View at Google Scholar · View at Scopus
  51. M. Rusckowski, G. Paganelli, D. J. Hnatowich et al., “Imaging osteomyelitis with streptavidin and Indium-111-labeled biotin,” Journal of Nuclear Medicine, vol. 37, no. 10, pp. 1655–1662, 1996. View at Google Scholar · View at Scopus
  52. C. J. Palestro and M. A. Torres, “Radionuclide imaging of nonosseous infection,” Quarterly Journal of Nuclear Medicine, vol. 43, no. 1, pp. 46–60, 1999. View at Google Scholar · View at Scopus
  53. E. Outwater, E. Oates, and R. C. Sarno, “Indium-111-labeled leukocyte scintigraphy: diagnosis of subperiosteal abscesses complicating osteomyelitis in a child,” Journal of Nuclear Medicine, vol. 29, no. 11, pp. 1871–1874, 1988. View at Google Scholar · View at Scopus
  54. F. L. Datz and D. A. Thorne, “Cause and significance of cold bone defects on Indium-111-labeled leukocyte imaging,” Journal of Nuclear Medicine, vol. 28, no. 5, pp. 820–823, 1987. View at Google Scholar · View at Scopus
  55. K. Uno, N. Matsui, and K. Nohira, “Indium-111 leukocyte imaging in patients with rheumatoid arthritis,” Journal of Nuclear Medicine, vol. 27, no. 3, pp. 339–344, 1986. View at Google Scholar · View at Scopus
  56. D. S. Schauwecker, H. M. Park, R. W. Burt, B. H. Mock, and H. N. Wellman, “Combined bone scintigraphy and indium-111 leukocyte scans in neuropathic foot disease,” Journal of Nuclear Medicine, vol. 29, no. 10, pp. 1651–1655, 1988. View at Google Scholar · View at Scopus
  57. L. M. Lamki, L. P. Kasi, and T. P. Haynie, “Localization of Indium-111 leukocytes in noninfected neoplasms,” Journal of Nuclear Medicine, vol. 29, no. 12, pp. 1921–1926, 1988. View at Google Scholar · View at Scopus
  58. C. J. Palestro, H. H. Mehta, M. Patel et al., “Marrow versus infection in the Charcot joint: indium-111 leukocyte and technetium-99m sulfur colloid scintigraphy,” Journal of Nuclear Medicine, vol. 39, no. 2, pp. 346–350, 1998. View at Google Scholar · View at Scopus
  59. W. J. G. Oyen, R. A. M. J. Claessens, J. W. M. Van der Meer, and F. H. M. Corstens, “Detection of subacute infectious foci with indium-111-labeled autologous leukocytes and indium-111-labeled human nonspecific immunoglobulin G: a prospective comparative study,” Journal of Nuclear Medicine, vol. 32, no. 10, pp. 1854–1860, 1991. View at Google Scholar · View at Scopus
  60. J. G. McAfee, G. Gagne, G. Subramanian, and R. F. Schneider, “The localization of indium-111-leukocytes, gallium-67-polyclonal IgG and other radioactive agents in acute focal inflammatory lesions,” Journal of Nuclear Medicine, vol. 32, no. 11, pp. 2126–2131, 1991. View at Google Scholar · View at Scopus
  61. C. J. Palestro, C. K. Kim, A. J. Swyer, S. Vallabhajosula, and S. J. Goldsmith, “Radionuclide diagnosis of vertebral osteomyelitis: indium-111-leukocyte and technetium-99m-methylene diphosphonate bone scintigraphy,” Journal of Nuclear Medicine, vol. 32, no. 10, pp. 1861–1865, 1991. View at Google Scholar · View at Scopus
  62. F. L. Datz, “Indium-111-labeled leukocytes for the detection of infection: current status,” Seminars in Nuclear Medicine, vol. 24, no. 2, pp. 92–109, 1994. View at Google Scholar · View at Scopus
  63. S. L. Kipper, “Radiolabelled leukocyte imaging of the abdomen,” in Nuclear Medicine Annual, L. M. Freeman, Ed., pp. 81–126, Raven Press, New York, NY, USA, 1995. View at Google Scholar
  64. J. H. Thrall and H. A. Ziessman, “Infection and inflammation,” in Nuclear Medicine: The Requisites, J. H. Thrall, Ed., pp. 167–192, Mosby, 2nd edition, 2001. View at Google Scholar
  65. M. E. Roddie, A. M. Peters, H. J. Danpure et al., “Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes,” Radiology, vol. 166, no. 3, pp. 767–772, 1988. View at Google Scholar · View at Scopus
  66. M. Vorne, I. Soini, T. Lantto, and S. Paakkinen, “Technetium-99m HM-PAO-labeled leukocytes in detection of inflammatory lesions: comparison with Gallium-67 citrate,” Journal of Nuclear Medicine, vol. 30, no. 8, pp. 1332–1336, 1989. View at Google Scholar · View at Scopus
  67. I. Hovi, M. Taavitsainen, T. Lantto, M. Vorne, R. Paul, and K. Remes, “Technetium-99m-HMPAO-labeled leukocytes and technetium-99m-labeled human polyclonal immunoglobulin G in diagnosis of focal purulent disease,” Journal of Nuclear Medicine, vol. 34, no. 9, pp. 1428–1434, 1993. View at Google Scholar · View at Scopus
  68. E. H. Lantto, T. J. Lantto, and M. Vorne, “Fast diagnosis of abdominal infections and inflammations with technetium-99m-HMPAO labeled leukocytes,” Journal of Nuclear Medicine, vol. 32, no. 11, pp. 2029–2034, 1991. View at Google Scholar · View at Scopus
  69. E. H. Lantto, T. J. Lantto, and M. Vorne, “Fast diagnosis of abdominal infections and inflammations with technetium-99m-HMPAO labeled leukocytes,” Journal of Nuclear Medicine, vol. 32, no. 11, pp. 2029–2034, 1991. View at Google Scholar · View at Scopus
  70. F. Palermo, F. Boccaletto, A. Paolin et al., “Comparison of technetium-99m-MDP, technetium-99-m-WBC and technetium- 99m-HIG in musculoskeletal inflammation,” Journal of Nuclear Medicine, vol. 39, no. 3, pp. 516–521, 1998. View at Google Scholar · View at Scopus
  71. W. Becker, U. Borst, W. Fischbach, B. Pasurka, R. Schafer, and W. Borner, “Kinetic data of in-vivo labeled granulocytes in humans with a murine Tc-99m-labelled monoclonal antibody,” European Journal of Nuclear Medicine, vol. 15, no. 7, pp. 361–366, 1989. View at Google Scholar · View at Scopus
  72. W. S. Becker, A. Saptogino, and F. G. Wolf, “The single late 99Tcm granulocyte antibody scan in inflammatory diseases,” Nuclear Medicine Communications, vol. 13, no. 3, pp. 186–192, 1992. View at Google Scholar · View at Scopus
  73. W. Becker, J. Bair, T. Behr et al., “Detection of soft-tissue infections and osteomyelitis using a technetium- 99m-labeled anti-granulocyte monoclonal antibody fragment,” Journal of Nuclear Medicine, vol. 35, no. 9, pp. 1436–1443, 1994. View at Google Scholar · View at Scopus
  74. M. L. Thakur, C. S. Marcus, P. Henneman et al., “Imaging inflammatory diseases with neutrophil-specific technetium-99m- labeled monoclonal antibody anti-SSEA-1,” Journal of Nuclear Medicine, vol. 37, no. 11, pp. 1789–1795, 1996. View at Google Scholar · View at Scopus
  75. S. L. Kipper, E. B. Rypins, D. G. Evans, M. L. Thakur, T. D. Smith, and B. Rhodes, “Neutrophil-specific 99mTc-labeled anti-CD 15 monoclonal antibody imaging for diagnosis of equivocal appendicitis,” Journal of Nuclear Medicine, vol. 41, no. 3, pp. 449–455, 2000. View at Google Scholar · View at Scopus
  76. S. Gratz, T. Behr, A. Herrmann et al., “Intraindividual comparison of 99mTc-labelled anti-SSEA-1 antigranulocyte antibody and 99mTc-HMPAO labelled white blood cells for the imaging of infection,” European Journal of Nuclear Medicine, vol. 25, no. 4, pp. 386–393, 1998. View at Publisher · View at Google Scholar · View at Scopus
  77. W. Becker, D. M. Goldenberg, and F. Wolf, “The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions,” Seminars in Nuclear Medicine, vol. 24, no. 2, pp. 142–153, 1994. View at Google Scholar · View at Scopus
  78. A. J. Fischman, M. C. Pike, D. Kroon et al., “Imaging focal sites of bacterial infection in rats with indium-111- labeled chemotactic peptide analogs,” Journal of Nuclear Medicine, vol. 32, no. 3, pp. 483–491, 1991. View at Google Scholar · View at Scopus
  79. J. W. Babich, W. Graham, S. A. Barrow et al., “Technetium-99m-labeled chemotactic peptides: comparison with Indium-111- labeled white blood cells for localizing acute bacterial infection in the rabbit,” Journal of Nuclear Medicine, vol. 34, no. 12, pp. 2176–2181, 1993. View at Google Scholar · View at Scopus
  80. A. J. Fischman, D. Rauh, H. Solomon et al., “In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates,” Journal of Nuclear Medicine, vol. 34, no. 12, pp. 2130–2134, 1993. View at Google Scholar · View at Scopus
  81. J. W. Babich, Q. Dong, W. Graham et al., “A novel high affinity chemotactic peptide antagonist for infection imaging,” Journal of Nuclear Medicine, vol. 38: 268, 1997. View at Google Scholar
  82. A. D. Luster, “Mechanisms of disease: chemokines-chemotactic cytokines that mediate inflammation,” New England Journal of Medicine, vol. 338, no. 7, pp. 436–445, 1998. View at Publisher · View at Google Scholar · View at Scopus
  83. C. J. Van der Laken, O. C. Boerman, W. J. G. Oyen et al., “Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model,” European Journal of Nuclear Medicine, vol. 22, no. 11, pp. 1249–1255, 1995. View at Publisher · View at Google Scholar · View at Scopus
  84. C. J. vanderLaken, O. C. Boerman, W. J. G. Oyen et al., “Comparison of radiolabeled human recombinant interleukin-1 with its receptor antagonist in a model of infection,” European Journal of Nuclear Medicine, vol. 22: 916, 1995. View at Google Scholar
  85. A. Signore, M. Chianelli, A. Annovazzi et al., “123I-Interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease,” Journal of Nuclear Medicine, vol. 41, no. 2, pp. 242–249, 2000. View at Google Scholar · View at Scopus
  86. A. Signore, M. Chianelli, A. Annovazzi et al., “Imaging active lymphocytic infiltration in coeliac disease with iodine- 123-interleukin-2 and the response to diet,” European Journal of Nuclear Medicine, vol. 27, no. 1, pp. 18–24, 2000. View at Google Scholar · View at Scopus
  87. M. D. Gross, B. Shapiro, R. S. Skinner, P. Shreve, L. M. Fig, and R. V. Hay, “Scintigraphy of osteomyelitis in man with human recombinant interleukin-8,” Journal of Nuclear Medicine, vol. 37: 25, 1996. View at Google Scholar
  88. R. V. Hay, R. S. Skinner, O. C. Newman et al., “Scintigraphy of acute inflammatory lesions in rats with radliolabelled recombinant human interleukin-8,” Nuclear Medicine Communications, vol. 18, no. 4, pp. 367–378, 1997. View at Google Scholar · View at Scopus
  89. C. J. Van Der Laken, O. C. Boerman, W. J. G. Oyen, M. T. P. Van De Ven, J. W. M. Van Der Meer, and F. H. M. Corstens, “Radiolabeled interleukin-8: specific scintigraphic detection of infection within a few hours,” Journal of Nuclear Medicine, vol. 41, no. 3, pp. 463–469, 2000. View at Google Scholar · View at Scopus
  90. H. J. J. M. Rennen, O. C. Boernan, W. J. G. Oyen, J. W. M. Van der Meer, and F. H. M. Corstens, “Specific and rapid scintigraphic detection of infection with 99mTc-labeled interleukin-8,” Journal of Nuclear Medicine, vol. 42, no. 1, pp. 117–123, 2001. View at Google Scholar · View at Scopus
  91. S. Gratz, H. J. J. M. Rennen, O. C. Boerman, W. J. G. Oyen, and F. H. M. Corstens, “Rapid imaging of experimental colitis with 99mTc-interleukin-8 in rabbits,” Journal of Nuclear Medicine, vol. 42, no. 6, pp. 917–923, 2001. View at Google Scholar · View at Scopus
  92. B. R. Moyer, S. Vallabhajosula, J. Lister-James et al., “Technetium-99m-White Blood Cell-Specific Imaging Agent Developed from Platelet Factor 4 to Detect Infection,” Journal of Nuclear Medicine, vol. 37, no. 4–6, pp. 673–679, 1996. View at Google Scholar · View at Scopus
  93. C. J. Palestro, M. B. Tomas, K. K. Bhargava et al., “Tc-99m P483H for imaging infection: phase 2 multicenter trial results,” Journal of Nuclear Medicine, vol. 40:15, 1999. View at Google Scholar
  94. G. I. Bell, C. F. Burant, J. Takeda, and G. W. Gould, “Structure and function of mammalian facilitative sugar transporters,” Journal of Biological Chemistry, vol. 268, no. 26, pp. 19161–19164, 1993. View at Google Scholar · View at Scopus
  95. E. K. J. Pauwels, M. J. Ribeiro, J. H. M. B. Stoot, V. R. McCready, M. Bourguignon, and B. Mazière, “FDG accumulation and tumor biology,” Nuclear Medicine and Biology, vol. 25, no. 4, pp. 317–322, 1998. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Zhuang and A. Alavi, “18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation,” Seminars in Nuclear Medicine, vol. 32, no. 1, pp. 47–59, 2002. View at Google Scholar · View at Scopus
  97. J. Y. Paik, K. H. Lee, S. C. Yearn, Y. Choi, and B. T. Kim, “Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C,” Journal of Nuclear Medicine, vol. 45, no. 1, pp. 124–128, 2004. View at Google Scholar · View at Scopus
  98. P. D. Shreve, Y. Anzai, and R. L. Wahl, “Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants,” Radiographics, vol. 19, no. 1, pp. 61–77, 1999. View at Google Scholar · View at Scopus
  99. T. Nakahara, H. Fujii, M. Ide et al., “FDG uptake in the morphologically normal thymus: comparison of FDG position emission tomography and CT,” British Journal of Radiology, vol. 74, pp. 821–824, 2001. View at Google Scholar
  100. C. Love, M. B. Tomas, G. G. Tronco, and C. J. Palestro, “FDG PET of infection and inflammation,” Radiographics, vol. 25, no. 5, pp. 1357–1368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Guhlmann, D. Brecht-Krauss, G. Suger et al., “Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis,” Journal of Nuclear Medicine, vol. 39, no. 12, pp. 2145–2152, 1998. View at Google Scholar · View at Scopus
  102. Y. Sugawara, D. K. Braun, P. V. Kison, J. E. Russo, K. R. Zasadny, and R. L. Wahl, “Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results,” European Journal of Nuclear Medicine, vol. 25, no. 9, pp. 1238–1243, 1998. View at Publisher · View at Google Scholar · View at Scopus
  103. R. F. Yen, Y. C. Chen, Y. W. Wu, M. H. Pan, and S. C. Chang, “Using 18-fluoro-2-deoxyglucose position emission tomography in detecting infectious endocarditis/endoarteritis: a preliminary report,” Academic Radiology, vol. 11, pp. 316–321, 2004. View at Google Scholar
  104. A. Guhlmann, D. Brecht-Krauss, G. Suger et al., “Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings,” Radiology, vol. 206, no. 3, pp. 749–754, 1998. View at Google Scholar · View at Scopus
  105. T. Kälicke, A. Schmitz, J. H. Risse et al., “Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases,” European Journal of Nuclear Medicine, vol. 27, no. 5, pp. 524–528, 2000. View at Google Scholar · View at Scopus
  106. K. D. M. Stumpe, H. Dazzi, A. Schaffner, and G. K. Von Schulthess, “Infection imaging using whole-body FDG-PET,” European Journal of Nuclear Medicine, vol. 27, no. 7, pp. 822–832, 2000. View at Google Scholar · View at Scopus
  107. M. Schiesser, K. D. M. Stumpe, O. Trentz, T. Kossmann, and G. K. Von Schulthess, “Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results,” Radiology, vol. 226, no. 2, pp. 391–398, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. C. Love and C. J. Palestro, “18F-FDG and 67Ga-SPECT imaging in suspected vertebral osteomyelitis: an intraindividual comparison,” Journal of Nuclear Medicine, vol. 45, supplement: 148, 2003. View at Google Scholar
  109. S. Yamada, K. Kubota, R. Kubota, T. Ido, and N. Tamahashi, “High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue,” Journal of Nuclear Medicine, vol. 36, no. 7, pp. 1301–1306, 1995. View at Google Scholar · View at Scopus
  110. Z. Keidar, D. Militianu, E. Melamed, R. Bar-Shalom, and O. Israel, “The diabetic foot: initial experience with 18F-FDG PET/CT,” Journal of Nuclear Medicine, vol. 46, no. 3, pp. 444–449, 2005. View at Google Scholar · View at Scopus
  111. A. Kjaer, A. M. Lebech, A. Eigtved, and L. Højgaard, “Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 5, pp. 622–626, 2004. View at Google Scholar · View at Scopus
  112. D. C. Hooper, J. S. Wolfson, E. Y. Ng, and M. N. Swartz, “Mechanisms of action of and resistance to ciprofloxacin,” American Journal of Medicine, vol. 82, no. 4, pp. 12–20, 1987. View at Google Scholar · View at Scopus
  113. S. Vinjamuri, A. V. Hall, K. K. Solanki et al., “Comparison of 99mTc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection,” Lancet, vol. 347, no. 8996, pp. 233–235, 1996. View at Google Scholar · View at Scopus
  114. A. V. Hall, K. K. Solanki, S. Vinjamuri et al., “Evaluation of the efficacy of 99mTc-Infecton: a novel agent for detecting sites of infection,” Journal of Clinical Pathology, vol. 51, pp. 215–219, 1996. View at Google Scholar
  115. J. L. Martinez, A. Alonso, J. M. Gonez-Gomez, and F. Baquero, “Quinolone resistance by mutations in chromosomal gyrase genes,” Journal of Antimicrobial Chemotherapy, vol. 42, pp. 683–671, 1998. View at Google Scholar
  116. F. De Winter, C. Van de Wiele, F. Dumont et al., “Biodistribution and dosimetry of 99mTc-ciprofloxacin, a promising agent for the diagnosis of bacterial infection,” European Journal of Nuclear Medicine, vol. 28, no. 5, pp. 570–574, 2001. View at Publisher · View at Google Scholar · View at Scopus
  117. K. E. Britton, S. Vinjamuri, A. V. Hall et al., “Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection,” European Journal of Nuclear Medicine, vol. 24, no. 5, pp. 553–556, 1997. View at Publisher · View at Google Scholar · View at Scopus
  118. K. E. Britton, D. W. Wareham, S. S. Das et al., “Imaging bacterial infection with 99mTc-Ciprofloxacin (infecton),” Journal of Clinical Pathology, vol. 55, pp. 817–823, 2002. View at Google Scholar
  119. A. K. Singh, J. Verma, A. Bhatnagar, and A. Ali, “99mTc-labelled sparfloxacin: a specific infection imaging agent,” World Journal of Nuclear Medicine, vol. 1, pp. 103–109, 2003. View at Google Scholar
  120. R. H. Siaens, H. J. Rennen, O. C. Boerman, R. Dierckx, and G. Slegers, “Synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin,” Journal of Nuclear Medicine, vol. 45, no. 12, pp. 2088–2094, 2004. View at Google Scholar · View at Scopus
  121. V. Gomes Barreto, F. Iglesias, M. Roca, F. Tabau, and J. Martin-Comin, “Labelling of cefizoxime with 99mTc,” Revista Española de Medicina Nuclear, vol. 19, pp. 479–483, 2000. View at Google Scholar
  122. J. Verma, A. k. Singh, A. Bhatnagar et al., “Radio-labeling of Ethambutol with technetium-99m and its evaluation for detection of tuberculosis,” World Journal of Nuclear Medicine, vol. 4, pp. 35–46, 2005. View at Google Scholar
  123. A. K. Singh, J. Verma, A. Bhatnagar, S. Sen, and M. Bose, “Tc-99m isoniazid: a specific agent for diagnosis of tuberculosis,” World Journal of Nuclear Medicine, vol. 2, pp. 292–305, 2003. View at Google Scholar
  124. A. Lupetti, M. M. Welling, U. Mazzi, P. H. Nibbering, and E. K. Pauwels, “Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections,” European Journal of Nuclear Medicine, vol. 29, no. 5, pp. 674–679, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Lupetti, M. M. Welling, E. K. J. Pauwels, and P. H. Nibbering, “Radiolabelled antimicrobial peptides for infection detection,” Lancet Infectious Diseases, vol. 3, no. 4, pp. 223–229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. A. J. Fischman, J. W. Babich, and H. W. Strauss, “A ticket to ride: peptide radiopharmaceuticals,” Journal of Nuclear Medicine, vol. 34, no. 12, pp. 2253–2263, 1993. View at Google Scholar · View at Scopus
  127. D. Blok, R. I. J. Feitsma, P. Vermeij, and E. J. K. Pauwels, “Peptide radiopharmaceuticals in nuclear medicine,” European Journal of Nuclear Medicine, vol. 26, no. 11, pp. 1511–1519, 1999. View at Publisher · View at Google Scholar · View at Scopus
  128. P. H. Nibbering, M. M. Welling, P. J. Van Den Broek, K. E. Van Wyngaarden, E. K. J. Pauwels, and W. Calame, “Radiolabelled antimicrobial peptides for imaging of infections: a review,” Nuclear Medicine Communications, vol. 19, no. 12, pp. 1117–1121, 1998. View at Google Scholar · View at Scopus
  129. R. M. Epand and H. J. Vogel, “Diversity of antimicrobial peptides and their mechanisms of action,” Biochimica et Biophysica Acta, vol. 1462, no. 1-2, pp. 11–28, 1999. View at Publisher · View at Google Scholar · View at Scopus
  130. A. Lupetti, P. H. Nibbering, M. M. Welling, and E. K. J. Pauwels, “Radiopharmaceuticals: new antimicrobial agents,” Trends in Biotechnology, vol. 21, no. 2, pp. 70–73, 2003. View at Publisher · View at Google Scholar · View at Scopus
  131. S. M. Okarvi, “Recent developments in 99Tcm-labelled peptide-based radiopharmaceuticals: an overview,” Nuclear Medicine Communications, vol. 20, no. 12, pp. 1093–1112, 1999. View at Google Scholar · View at Scopus
  132. E. K. J. Pauwels, M. M. Welling, R. I. J. Feitsma, D. E. Atsma, and W. Nieuwenhuizen, “The labeling of proteins and LDL with 99mTc: a new direct method employing KBH4 and stannous chloride,” Nuclear Medicine and Biology, vol. 20, no. 7, pp. 825–833, 1993. View at Publisher · View at Google Scholar · View at Scopus
  133. M. M. Welling, A. Paulusma-Annema, H. S. Balter, E. K. J. Pauwels, and P. H. Nibbering, “Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations,” European Journal of Nuclear Medicine, vol. 27, no. 3, pp. 292–301, 2000. View at Google Scholar · View at Scopus
  134. M. M. Welling, P. S. Hiemstra, M. T. Van Den Barselaar et al., “Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation,” Journal of Clinical Investigation, vol. 102, no. 8, pp. 1583–1590, 1998. View at Google Scholar · View at Scopus
  135. M. M. Welling, P. H. Nibbering, A. Paulusma-Annema, P. S. Hiemstra, E. K. J. Pauwels, and W. Calame, “Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1,” Journal of Nuclear Medicine, vol. 40, no. 12, pp. 2073–2080, 1999. View at Google Scholar · View at Scopus
  136. P. H. Nibbering, M. M. Welling, A. Paulusma-Annema, M. T. vandenBarselaar, and E. K. J. Pauwels, “Monitoring the efficacy of antibacterial treatments of infections with Tc-99m labeled antimicrobial peptides,” Nuclear Medicine Communications, vol. 21, pp. 575–576, 2000. View at Google Scholar
  137. P. S. Hiemstra, M. T. Van Den Barselaar, M. Roest, P. H. Nibbering, and R. Van Furth, “Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages,” Journal of Leukocyte Biology, vol. 66, no. 3, pp. 423–428, 1999. View at Google Scholar · View at Scopus
  138. G. Ferro-Flores, C. Arteaga De Murphy, M. Pedraza-López et al., “In vitro and in vivo assessment of 99mTc-UBI specificity for bacteria,” Nuclear Medicine and Biology, vol. 30, no. 6, pp. 597–603, 2003. View at Publisher · View at Google Scholar · View at Scopus
  139. D. Salber, J. Gunawan, K.-J. Langen et al., “Comparison of 99mTc-and 18F-ubiquicidin autoradiography to anti-staphylococcus aureus immunoflorescence in rat muscle abscesses,” Journal of Nuclear Medicine, vol. 49, pp. 995–999, 2008. View at Google Scholar
  140. L. Sarda-Mantel, A. Saleh-Mghir, M. M. Welling et al., “Evaluation of 99mTc-UBI 29-41 scintigraphy for specific detection of experimental Staphylococcus aureus prosthetic joint infections,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 8, pp. 1302–1309, 2007. View at Publisher · View at Google Scholar · View at Scopus
  141. C. P. J. M. Brouwer, F. F. A. Y. Gemmel, and M. M. Welling, “Evaluation of99mTc-UBI 29-41 scintigraphy for specific detection of experimental multidrug-resistant Staphylococcus aureus bacterial endocarditis,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, no. 4, pp. 442–450, 2010. View at Google Scholar · View at Scopus
  142. M. M. Welling, A. Lupetti, H. S. Balter et al., “99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections,” Journal of Nuclear Medicine, vol. 42, no. 5, pp. 788–794, 2001. View at Google Scholar · View at Scopus
  143. A. Lupetti, M. M. Welling, U. Mazzi, P. H. Nibbering, and E. K. Pauwels, “Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections,” European Journal of Nuclear Medicine, vol. 29, no. 5, pp. 674–679, 2002. View at Publisher · View at Google Scholar · View at Scopus
  144. P. H. Nibbering, M. M. Welling, A. Paulusma-Annema, C. P. J. M. Brouwer, A. Lupetti, and E. K. J. Pauwels, “99mTc-labeled UBI 29–41 peptide for monitoring the efficacy of antimicrobial agents in mice infected with staphylococcus aureus,” Journal of Nuclear Medicine, vol. 45, pp. 321–326, 2004. View at Google Scholar
  145. L. Meléndez-Alafort, J. Rodríguez-Cortés, G. Ferro-Flores et al., “Biokinetics of 99mTc-UBI 29-41 in humans,” Nuclear Medicine and Biology, vol. 31, no. 3, pp. 373–379, 2004. View at Publisher · View at Google Scholar · View at Scopus
  146. E. Vallejo, I. Martinz, A. Tejero, S. Hermandez et al., “Clinical utility of 99mTc-labeled ubiquicidin 29-41 antimicrobial peptide for sctigraphic detection of mediastinitis after cardiac surgery,” Archives of Medical Research, vol. 39, no. 8, pp. 768–774, 2008. View at Google Scholar
  147. J. Supulveda-Mendez, C. A. de Murphy, J. C. Rojas-Bautista, and M. Pedraza-Lopez, “Specificity of 99m-Tc-UBI for detecting foci in patients with fever in study,” Nuclear Medicine Communications, vol. 31, no. 10, pp. 889–895, 2010. View at Google Scholar
  148. C. Dillmann-Arroyo, R. Cantu-Leal, H. Camp-Nunez, C. Lopez-Carazosc et al., “Application of the ubiquicidin 29-41 scan in the diagnosis of pyogenic vertebral osteomyelitis,” Acta Ortopédica Mexicana, vol. 25, no. 1, pp. 27–31, 2011. View at Google Scholar
  149. M. Assadi, K. Vahdat, I. Nabipour, M. R. Sehhat, F. Hadanvand et al., “Diagnostic value of 99mTc-ubiquicidin scintigraphy for osteomyelitis and comparison with 99mTc-methylene diphosphonate scintigraphy and magnetic resonance imaging,” Nuclear Medicine Communications, vol. 32, no. 8, pp. 716–723, 2011. View at Google Scholar
  150. B. Nazari, Z. Azizmohammadi, M. Rajaei et al., “Role of 99mTc-ubiquicidin 29-41 scintigraphy to monitor antibiotic therapy in patients with orthopaedic infection: a preliminary study,” Nuclear Medicine Communications, vol. 32, no. 8, pp. 745–751, 2011. View at Google Scholar
  151. R. E. Bishop, H. S. Gibbons, T. Guina, M. S. Trent, S. I. Miller, and C. R. H. Raetz, “Transfer of palmitate from phospholipids to lipid A in outer membranes of Gram-negative bacteria,” EMBO Journal, vol. 19, no. 19, pp. 5071–5080, 2000. View at Google Scholar · View at Scopus
  152. A. Peschel, R. W. Jack, M. Otto et al., “Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine,” Journal of Experimental Medicine, vol. 193, no. 9, pp. 1067–1076, 2001. View at Publisher · View at Google Scholar · View at Scopus
  153. A. Peschel, “How do bacteria resist human antimicrobial peptides?” Trends in Microbiology, vol. 10, no. 4, pp. 179–186, 2002. View at Publisher · View at Google Scholar · View at Scopus
  154. M. H. Limoncu, S. Ermertcan, C. B. Cetin, G. Cosar, and G. Dinc, “Emergence of phenotypic resistance to ciprofloxacin and levofloxacin in methicillin resistant and methicillin-sensitive staphylococcus aureus strains,” International Journal of Antimicrobial Agents, vol. 5, pp. 420–424, 2003. View at Google Scholar